We showed that methylazoxymethanol (MAM), the genotoxic metabolite of the cycad plant carcinogen cycasin (MAM- 1 This supports an etiologic role for the azoxyglycoside cycasin in the genesis of a disappearing degenerative brain disease (amyotrophic lateral sclerosis and parkinsonism-dementia complex, ALS-PDC) found among the genetically distinct island populations of Guam and Rota (Chamorros), Honshu (Japanese) and New Guinea (Papuan New Guinean), which used cycad seed as medicine applied orally (Kii Peninsula, Honshu) or topically (West Papua), or for both topical medicine and food (Guam and Rota). In all three disease foci, periods of years or decades intervene between exposure to cycad seed and the development of ALS-PDC, suggesting the operation of a "slow toxin" able to trigger a progressive neuronal disease reminiscent of look-a-like disorders of old age (e.g., Alzheimer disease, AD) elsewhere in the world. 2 Both AD and ALS-PDC have neurofibrillary tangles containing the microtubule tau protein in a hyperphosphorylated state, [3] [4] [5] which has been linked to both activation of serinethreonine kinases (Erk-1/2, p38, c-Jun NH 2 -terminal kinase) in the mitogenactivated protein kinase (MAPK) pathway and to phosphorylation of the C-terminal fragment of amyloid precursor protein (APP). 6 More recent studies suggest the activation of non-apoptotic caspases may ©2 0 1 1 L a n d e s B i o s c i e n c e . 12 The left half of each brain was analyzed by protein gel blotting for components of n = 4) or a comparable volume of vehicle consisting of 0.5% acetic acid in saline (n = 3). Animals were housed singly, fed rodent chow ad libitum for 6 mo, during which all animals grew and maintained apparent health, and then decapitated by guillotine.
D o n o t d i s t r i b u t e .
The right half of the MAM late brain was employed for gene expression analysis using mouse oligo microarrays (~21,000 features) by Agilent (Santa Clara, CA). As in the previously published MAM early study, 1 brain cellular networks putatively be one of the earliest events that triggers tau aggregation and the accumulation of neurofibrillary tangles in tauopathies.
7-9
Here, we supplement data on the shortterm actions (up to 7 d) of MAM on brain gene expression in O 6 -mG-deficient mice (MAM early ) with preliminary findings on caspase activity and the transcription and protein expression of brain cell signaling proteins 6 mo post-treatment (MAM late ).
Seven 11-week-old male Mgmt -/-mice were treated with a single intraperitoneal dose of MAM (20 mg/kg body weight, Huntington's disease 5 
©2 0 1 1 L a n d e s B i o s c i e n c e . D o n o t d i s t r i b u t e .
www.landesbioscience.com Communicative & Integrative Biologythe MAPK (perturbed in both MAM late and MAM early ) and phosphatidylinositol-3-kinase/Akt (PI3K/Akt) signaling pathways and activity of caspase-3 (the APP cleavage protein linked to AD). 8, 9 In MAM late , significant increases were found in Erk-1 (p < 0.03) and fodrin cleavage (p < 0.01) (Fig. 1) . Brain fodrin cleavage, which was increased in MAM late animals, indicates the activation of caspase-3, an enzyme with an important role in cleaving tau.
14 MAM late transcriptional changes in extracellular-matrix-receptor interaction (4 genes upregulated, 1 downregulated gene) and cytokine-cytokine receptor interaction (3 genes upregulated, 2 downregulated genes) suggest brain inflammatory response modulation, which is consistent with early changes in taurelated neurodegeneration. 15 The MAM late transcriptional profile was dominated by the presence of 28 (of a total of ~1,300) genes involved in olfactory transduction, 16 including chloride channel activated 6, which suggest the presence of a MAM-induced change in olfaction status. While caution is merited when comparing rodent and human data, olfactory dysfunction is among the first signs of neurodegenerative disease. 17 Marked olfactory deficits, first reported in Guam PDC, are also similarly present in Chamorro patients with ALS, pure parkinsonism and pure dementia, and in some controls with possible sub-clinical ALS-PDC. 18 Olfactory deficits are also among the first signs of Alzheimer disease and idiopathic Parkinson disease. 19, 20 The inability to distinguish the nature of olfactory dysfunction among Guam PDC, AD 21 and ALS patients 18 suggests a common neurologic substrate and underlines the close relationship between ALS-PDC and the more familiar neurodegenerative disorders seen in the West. -/-mice were flash frozen in liquid N 2 , the frozen tissue subjected to ultrasonication in gel electrophoresis buffer to avoid loss of protein modifications or lysis, and the homogenate heat-denatured at 95°C for 5 min. an aliquot of the brain tissue homogenate (50 μg) was resolved on a 10% polyacrylamide gel, transferred to PVDF membranes, the blocked membranes probed with monoclonal antibodies to erK (erK1, erK2), phosphorylated erK (perK1, perK2), PI3K (p110γ) (Santa Cruz Biotechnology, Inc.,) and α-fodrin (Chemicon), and the bands visualized by chemiluminescence detection. α-Fodrin cleavage was determined using the 120 kDa band. membranes were scanned on a microtek flatbed scanner and each band quantified using molecular analyst software (Biorad, Inc.), with background subtraction as described previously in reference 13. Values are the mean ± standard error. Significantly different from vehicle (*p < 0.03 or **p < 0.01 by aNOVa).
